TheraRadar
Data updated: May 26, 2026

SIGNIFOR LAR KIT (pasireotide pamoate)

Endocrine Approved 2014-12-15
Jump to: Indications Approvals Trials Competitors Safety Patents
2
Indications
--
Phase 3 Trials
11
Years on Market

Details

Status
Prescription
First Approved
2014-12-15
Patent Cliff
2028

Pro Metrics

Patent cliff and revenue data

Unlock with Pro
Routes
INTRAMUSCULAR
Dosage Forms
FOR SUSPENSION

Companies

RECORDATI RARE
Active Ingredient: PASIREOTIDE PAMOATE

SIGNIFOR LAR KIT Approval History

2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
40 FDA actions from 2014 to 2024 · 1 indication expansions
Jul 2024 SUPPL
Label · Labeling
FDA Letter Label
Jul 2020 SUPPL
Label · Labeling
FDA Letter Label
Apr 2019 SUPPL
Label · Labeling
FDA Letter Label

What SIGNIFOR LAR KIT Treats

2 FDA approvals

Originally approved for its first indication in 2014 . Covers 2 distinct patient populations.

  • Other (2)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

SIGNIFOR LAR KIT FDA Label Details

View full patent landscape →
3 OB patents · 3 families · 178 international docs across 56 countries

SIGNIFOR LAR KIT Patents & Exclusivity

Latest Patent: May 2028

Patents (3 active)

US9351923 Expires May 23, 2028
US7473761 Expires Dec 14, 2026
US7759308 Expires Oct 25, 2026
Source: FDA Orange Book

Pro Intelligence Preview

Deep insights for SIGNIFOR LAR KIT

Revenue Insights

  • • Quarterly revenue tracking
  • • Historical trend analysis

Patent Timeline

  • • Cliff: 2028
  • • 75 active patents

Trial Analysis

  • • Clinical trial tracking
  • • Development stage analysis

Competitive Landscape

  • • Competitor tracking
  • • Same target/indication analysis
Unlock Full Intelligence

Full approval history • All patents • Revenue trends • Competitor analysis

Data Sources

FDA Approval: NDA203255 → Patents: FDA Orange Book → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.